Chronic Inflammation Overview

Principles

Definition

Chronic inflammation is an academic concept and research field focused on investigating the prolonged, often low-grade, inflammatory response characterized by simultaneous tissue injury and attempted repair. Its significance lies in its critical role in the pathogenesis and progression of numerous non-communicable diseases, including cardiovascular disorders, metabolic syndromes, neurodegenerative conditions, and cancer.

Ontological type

Disease Associations

Molecular Mechanisms

Therapeutic Strategies

Key developments

Key Figures

Cytokine Network Paradigm era

Anthony Cerami[1], with affiliations at Rockefeller University[3] and Harvard University[4], conducted influential work in this era. His key contributions include showing that tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1[7], establishing the identity of tumour necrosis factor and the macrophage-secreted factor cachectin[8], and describing macrophages secreting a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties[9], thereby defining a cytokine network that linked innate immunity to the acute-phase response. Joost J. Oppenheim[2], with affiliations at University of California, San Francisco[5] and the Weizmann Institute of Science[6], contributed to the era by elucidating leukocyte recruitment and cytokine signaling. His key contributions include molecular cloning of a human monocyte-derived neutrophil chemotactic factor and its induction by interleukin 1 and tumor necrosis factor[10], purification of a human monocyte-derived neutrophil chemotactic factor with sequence similarity to other host defense cytokines[11], and the analysis of macrophages in the acute-phase response with SAA inducer related to lymphocyte activating factor and endogenous pyrogen[12].

Signaling Hubs and Targeting era

Russell P. Tracy [1] is affiliated with Harvard University [3] and the University of California, San Francisco [4] during this era. His key contributions include advancing the use of inflammatory biomarkers to link chronic inflammation with cardiovascular disease, as exemplified by the 2003 paper 'Markers of Inflammation and Cardiovascular Disease' [6], which helped illuminate how inflammatory signals shape risk and informed hub-centric approaches to targeting inflammatory pathways. Nader Rifai [2] is affiliated with Harvard University [3] and Stanford University [5] in this era. His contributions, reflected in the same 2003 paper 'Markers of Inflammation and Cardiovascular Disease' [6], helped translate biomarker insights into risk assessment and underscored the translational value of hub-centric strategies for mitigating inflammation-related cardiovascular risk.

Immunometabolism and Inflammasomes era

Luke O'neill [1], affiliated with University of Cambridge [3] and University of Chicago [4] during this era. His key contributions include Succinate is an inflammatory signal that induces IL-1β through HIF-1α [7], Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1 [8], and Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes [9], collectively linking metabolic cues to inflammasome activation and IL-1β production in this era. Luigi Franchi [2], affiliated with University of Bonn [5] and University of Michigan [6] contributed to the understanding that NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [10], that Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes [9], and Cutting Edge: TNF-α Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial Stimulation [11]. These contributions underscored immunometabolic rewiring as a determinant of inflammatory persistence and resolution in tissue contexts, guiding translational efforts toward NLRP3 inhibitors [11] and metabolism-focused therapeutics [10] in this era.